Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy

Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy

Ying Zheng,1 Ting Yu,2 Rachel H Mackey,3,4 Julie A Gayle,3 Christina L Wassel,3 Hemant Phatak,1 Ruth Kim5 1 EMD Serono, Inc., Rockland, USA; An Affiliate of Merck KGaA, Darmstadt, Germany; 2Global Medical Affairs, EMD Serono, Inc., Rockland, MA, USA; An Affiliate of Merck KGaA, Darmstadt, Germany; 3...

Full description

Bibliographic Details
Main Authors: Zheng Y, Yu T, Mackey RH, Gayle JA, Wassel CL, Phatak H, Kim R
Format: Article
Language:English
Published: Dove Medical Press 2021-03-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
metastatic merkel cell carcinoma
immune checkpoint inhibitors
chemotherapy
Online Access:https://www.dovepress.com/clinical-outcomes-costs-and-healthcare-resource-utilization-in-patient-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/clinical-outcomes-costs-and-healthcare-resource-utilization-in-patient-peer-reviewed-article-CEOR

Similar Items